Palella Jr FJ, Delaney KM, Moorman AC.
et al. for the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human
immunodeficiency virus infection. N Engl J Med.1998;338:853-860.
Gebhardt M, Rickenbach M, Egger M. Impact of antiretroviral combination therapies on AIDS surveillance
reports in Switzerland: Swiss HIV Cohort Study. AIDS.1998;12:1195-1201.
Brettle RP, Wilson A, Povey S.
et al. Combination therapy for HIV: the effect on inpatient activity, morbidity
and mortality of a cohort of patients. Int J STD AIDS1998;9:80-87.
Fleming PL, Ward JW, Karon JM, Hanson DL, De Cock KM. Declines in AIDS incidence and deaths in the USA: a signal change in
the epidemic. AIDS.1998; 12:S55-S61.
Hammer SM, Squires KE, Hughes MD.
et al. A controlled trial of two nucleoside analogues plus indinavir in persons
with human immunodeficiency virus infection and CD4 cell counts of 200 per
cubic millimeter or less. N Engl J Med.1997;337:725-733.
Cameron DW, Heath-Chiozzi M, Danner S.
et al. Randomised placebo-controlled trial of
ritonavir in advanced HIV-1 disease. Lancet.1998;351:543-549.
Not Available. Delta: a randomized double-blind controlled trial comparing combinations
of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected
Hammer SM, Katzenstein DA, Hughes MD.
et al. A trial comparing nucleoside monotherapy with combination therapy in
HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med.1996;335:1081-1090.
Gazzard B, Moyle G.for the BHIVA Guidelines Writing Committee. 1998 revision to the British HIV Association guidelines for antiretroviral
treatment of HIV seropositive individuals. Lancet.1998;352:314-316.
Carpenter CC, Fischl MA, Hammer SM.
et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations
of the International AIDS Society-USA Panel. JAMA.1998;280:78-86.
Department of Health and Human Services and Henry J. Kaiser Family
Foundation.. Guidelines for the use of antiretroviral agents in HIV-infected adults
and adolescents. MMWR Morb Mortal Wkly Rep.1998;47:43-82.
Finzi D, Hermankova M, Pierson T.
et al. Identification of a reservoir for HIV-1 in patients on highly active
antiretroviral therapy. Science.1997;278:1295-1300.
Chun TW, Stuyver L, Mizell SB.
et al. Presence of an inducible HIV-1 latent reservoir during highly active
antiretroviral therapy. Proc Natl Acad Sci U S A.1997;94:13193-13197.
Balzarini J, Zhang H, Herdewijn P, Johns D, De Clercq E. Intracellular metabolism and mechanism of antiretrovirus action of
9-(2-phosphonylmethoxy) adenine, a potent anti-human immunodeficiency virus
compound. Proc Natl Acad Sci U S A.1991;88:1499-1503.
Bronson JJ, Kim CU, Ghazzouli I, Hitchcock MJM, Kern ER, Martin JC. Synthesis and antiviral activity of phosphonylmethoxyethyl derivatives
of purine and pyrimidine bases. Am Chem Soc Symp.1989;401:72-87.
Neyts J, Stahls F, Bruggeman C, De Clercq E. Activity of the anti-HIV agent 9-(2-phosphonylmethoxyethyl)-2-6-diaminopurine
against cytomegalovirus in vitro and in vivo. Eur J Clin Microbiol Infect Dis.1993;12:437-446.
Balzarini J, Perno CF, Schols D, De Clercq E. Activity of acyclic nucleoside phosphonate analogues against human
immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes. Biochem Biophys Res Commun.1991;178:329-335.
Kramata P, Votruba I, Otová B, Holt A. Different inhibitory potencies of acyclic phosphonomethoxyalkyl nucleotide
analogs toward DNA polymerases alpha, delta and epsilon. Mol Pharmacol.1996;49:1005-1011.
De Clercq E, Sakuma T, Baba M.
et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines
and pyrimidines. Antiviral Res.1987;8:261-272.
Miller MD, Anton KE, Mulato AS, Lamy PD, Cherrington JM. Human immunodeficiency virus type 1 expressing the lamivudine-associated
M184V mutation in reverse transcriptase shows increased susceptibility to
adefovir and decreased replication capacity. J Infect Dis.1999;179:92-100.
Barditch-Crovo P, Toole J, Hendrix CW.
et al. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics
of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl) phosphonylmethoxyethyl]
adenine) in HIV-infected patients. J Infect Dis.1997;176:406-413.
Deeks SG, Collier A, Lalezari J.
et al. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency
virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled
trial. J Infect Dis.1997;176:1517-1523.
Holme E, Greter J, Jacobson CE.
et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet.1989;2:469-473.
Bradley JV. Distribution-Free Statistical Tests. Englewood Cliffs, NJ: Prentice-Hall; 1968.
Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics.1982;38:963-974.
Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: Wiley & Sons; 1980.
Bailar III JC, Mosteller F. Medical Uses of Statistics. 2nd ed. Boston, Mass: NEJM Books; 1992.
Larder BA, Kellam P, Kemp SD. Zidovudine resistance predicted by direct detection of mutations in
DNA from HIV-infected lymphocytes. AIDS.1991;5:137-144.
Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level
resistance to zidovudine (AZT). Science.1989;246:1155-1158.
Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase
contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A.1992;89:1934-1938.
Katlama C, Clotet B, Plettenberg A, Purdon S, Goh L, Cutrell A.for the CNA3002 International Study Team. Intensification of stable background antiretroviral therapy with Abacavir
(ABC, 1592): 16 week data. In: Program and abstracts of the 4th International Congress on Drug
Therapy in HIV Infection; November 8-12,1998; Glasgow, Scotland. Abstract
Gallant J, Beal J, Myers R.
et al. Randomized, double-blind study of adefovir dipivoxil (ADV) at two dose
levels in combination with nucleoside reverse transcriptase inhibitors (NRTI)
and protease inhibitors (PI) for NRTI-experienced PI-naïve patients. In: Program and abstracts of the 39th Interscience Conference on
Antimicrobial Agents and Chemotherapy; September 26-29, 1999; San Francisco,
Calif. Abstract 1976.